PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17867559-4	2007	The results showed that the increased cell numbers and enhanced [3H]thymidine incorporation induced by ET-1 were inhibited and the transition of cells from static phase (G0/G1) to DNA synthesis (S) and mitotic phase (G2/M) was held back by lobeline in a concentration-dependent manner.	Lobeline	240-248	endothelin 1	Homo sapiens	103-107
17867559-0	2007	A novel effect of lobeline on vascular smooth muscle cell: inhibition of proliferation induced by endothelin-1.	Lobeline	18-26	endothelin 1	Homo sapiens	98-110
17867559-8	2007	Lobeline inhibited the proliferation of human umbilical VSMCs induced by ET-1 in a dose-dependent manner and the anti-proliferative effect was involved in the reduce of increased [Ca2+]i, rather than nonspecific cytotoxicity.	Lobeline	0-8	endothelin 1	Homo sapiens	73-77
17867559-2	2007	Lobelia chinensis Lour, a traditional Chinese herb whose active ingredient is the alkaloid lobeline, demonstrated to antagonize the bioactive effect of endothelin-1 (ET-1) and prevent the proliferation of vascular smooth muscle cells (VSMCs) in hyperlipidemic rats.	Lobeline	91-99	endothelin 1	Homo sapiens	152-164
17867559-2	2007	Lobelia chinensis Lour, a traditional Chinese herb whose active ingredient is the alkaloid lobeline, demonstrated to antagonize the bioactive effect of endothelin-1 (ET-1) and prevent the proliferation of vascular smooth muscle cells (VSMCs) in hyperlipidemic rats.	Lobeline	91-99	endothelin 1	Homo sapiens	166-170
12604705-4	2003	Calculated apparent K(i) values for the choline transporter were 1.7 microM N-n-octyl choline, 2.2 microM N-n-hexyl choline, 27 microM N-n-decylnicotinium iodide, 31.9 microM N-n-octylpyridinium iodide, 49 microM N-n-octylnicotinium iodide (NONI), 393 microM lobeline, and >/=1000 microM N-methylnicotinium iodide.	Lobeline	259-267	solute carrier family 6 member 8	Rattus norvegicus	40-59
17867559-3	2007	The objective of the present study was to determine the effects of lobeline on proliferation of cultured human umbilical VSMCs induced by ET-1.	Lobeline	67-75	endothelin 1	Homo sapiens	138-142
16107155-1	2005	(-)-Lobeline (2R,6S,10S), an antagonist at nicotinic acetylcholine receptors (nAChRs), inhibits the neurochemical and behavioral effects of methamphetamine and inhibits dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) function.	Lobeline	0-12	solute carrier family 6 member 3	Homo sapiens	169-189
16107155-1	2005	(-)-Lobeline (2R,6S,10S), an antagonist at nicotinic acetylcholine receptors (nAChRs), inhibits the neurochemical and behavioral effects of methamphetamine and inhibits dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) function.	Lobeline	0-12	solute carrier family 6 member 3	Homo sapiens	191-194
16107155-1	2005	(-)-Lobeline (2R,6S,10S), an antagonist at nicotinic acetylcholine receptors (nAChRs), inhibits the neurochemical and behavioral effects of methamphetamine and inhibits dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) function.	Lobeline	0-12	solute carrier family 18 member A2	Homo sapiens	233-238
16107155-6	2005	Generally, all of these analogues had lower affinities at alpha4beta2 and alpha7 nAChRs compared to lobeline, thereby increasing selectivity for VMAT2.	Lobeline	100-108	solute carrier family 18 member A2	Homo sapiens	145-150
15331654-8	2005	The maintenance of hyperthermia during lobeline + METH exposure restored the effects of METH on decreases in VMAT-2 as well as dopamine and 5-HT content.	Lobeline	39-47	solute carrier family 18 member A2	Rattus norvegicus	109-115
15102929-5	2004	High concentrations of lobeline induced a statistically significant release of [3H]DA from HEK-hDAT-hVMAT2 cells, but only in the absence of DHTB, suggesting an hVMAT2-mediated effect.	Lobeline	23-31	solute carrier family 6 member 3	Homo sapiens	95-99
15102929-5	2004	High concentrations of lobeline induced a statistically significant release of [3H]DA from HEK-hDAT-hVMAT2 cells, but only in the absence of DHTB, suggesting an hVMAT2-mediated effect.	Lobeline	23-31	solute carrier family 18 member A2	Homo sapiens	100-106
15102929-5	2004	High concentrations of lobeline induced a statistically significant release of [3H]DA from HEK-hDAT-hVMAT2 cells, but only in the absence of DHTB, suggesting an hVMAT2-mediated effect.	Lobeline	23-31	solute carrier family 18 member A2	Homo sapiens	161-167
15102929-0	2004	Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system.	Lobeline	31-39	solute carrier family 6 member 3	Homo sapiens	67-87
15121762-10	2004	Lobelane and ketoalkene were 5-fold more potent (Ki = 0.92 and 1.35 microM, respectively) than lobeline (Ki = 5.46 microM) in inhibiting [3H]methoxytetrabenazine binding to VMAT2 in vesicle preparations.	Lobeline	95-103	solute carrier family 18 member A2	Homo sapiens	173-178
11841781-11	2002	The development of lobeline and lobeline analogs with targeted selectivity at VMAT2 represents a novel class of therapeutic agents having good potential as efficacious treatments for methamphetamine abuse.	Lobeline	32-40	solute carrier family 18 member A2	Rattus norvegicus	78-83
9255161-11	1997	Preinjection of blocking doses of unlabeled epibatidine, (-)-nicotine, lobeline and cytisine significantly inhibited [18F]FPH binding in thalamus and superior colliculus, but not in cerebellum, whereas drugs that interact with binding sites other than acetylcholine recognition sites of nAChR (e.g., mecamylamine, scopolamine, N-methylspiperone and ketanserin) had no effect on [18F]FPH accumulation in any of the brain regions examined.	Lobeline	71-79	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	287-292
9648873-7	1998	These results suggest that lobeline specifically interacts with DTBZ sites on VMAT2 to inhibit DA uptake into synaptic vesicles.	Lobeline	27-35	solute carrier family 18 member A2	Rattus norvegicus	78-83
9667769-6	1998	The nAChR agonists (-)nicotine, cytisine, and (+) epibatidine reduced the radioactivity due to [11C]A-84543 in the superior colliculus by 41%, 38%, and 27%, respectively, while lobeline, which also interacts with central nAChRs, produced a 24% inhibition.	Lobeline	177-185	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	4-9
11841781-5	2002	Reevaluation of the mechanism by which lobeline alters dopamine function reveals that its primary mechanism is inhibition of dopamine uptake and promotion of dopamine release from the storage vesicles within the presynaptic terminal, via an interaction with the tetrabenazine-binding site on the vesicular monoamine transporter (VMAT2).	Lobeline	39-47	solute carrier family 18 member A2	Rattus norvegicus	329-334
11841781-11	2002	The development of lobeline and lobeline analogs with targeted selectivity at VMAT2 represents a novel class of therapeutic agents having good potential as efficacious treatments for methamphetamine abuse.	Lobeline	19-27	solute carrier family 18 member A2	Rattus norvegicus	78-83
10806376-9	2000	The reaction was sensitive to inhibition by the CYP2D6-selective inhibitors quinidine, quinine, lobeline and norfluoxetine, whereas chemical inhibitors selective for other CYP isoforms failed to affect the reaction.	Lobeline	96-104	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	48-54
10806376-9	2000	The reaction was sensitive to inhibition by the CYP2D6-selective inhibitors quinidine, quinine, lobeline and norfluoxetine, whereas chemical inhibitors selective for other CYP isoforms failed to affect the reaction.	Lobeline	96-104	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	48-51
10665822-7	2000	In the presence of mecamylamine (a noncompetitive nAChR antagonist), the increase in DA content of striatal dialysate samples induced by either nicotine or lobeline was attenuated.	Lobeline	156-164	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	50-55
10567725-5	1999	However, some of the nAChR agonists at higher concentrations (1, 1-dimethyl-4-phenylpiperazinium (DMPP) and lobeline), besides their effects on presynaptic nAChRs, are able to inhibit the uptake of NE and 5-HT into nerve terminals, thereby their transmitter releasing effects are extended in time and space.	Lobeline	108-116	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	21-26
27105955-8	2016	In contrast, lobeline, the most thoroughly investigated Lobelia alkaloid, is an alpha4beta2-nicAchR antagonist, a poor free radical scavenger, and is a less potent DAT inhibitor.	Lobeline	13-21	solute carrier family 6 member 3	Rattus norvegicus	164-167
6502210-5	1984	The alkaloid nicotinic agonists, cytisine and lobeline, were potent inhibitors of binding, while acetylcholine in the presence of the cholinesterase inhibitor di-isopropylfluorophosphate was equipotent with (+)-nicotine.	Lobeline	46-54	butyrylcholinesterase	Rattus norvegicus	134-148
33897801-10	2021	Our study identified metergoline, pipercallosine, celacinnine, lobeline, cystodytin G, lycoperine A, hookerianamide J, and martefragin A as putative lead compounds against POP.	Lobeline	63-71	prolyl endopeptidase	Homo sapiens	172-175
28554528-10	2017	In contrast, repeated lobeline treatment significantly increased both BrdU- and BDNF-positive cells.	Lobeline	22-30	brain derived neurotrophic factor	Mus musculus	80-84
28554528-11	2017	Taken together, our results indicate that lobeline produced antidepressant-like effects, likely by targeting brain beta2-containing nAChRs, serotonergic neurotransmission, and/or hippocampal cell proliferation.	Lobeline	42-50	hemoglobin, beta adult minor chain	Mus musculus	115-120
8080088-5	1994	Furthermore, the O-demethylase activity in a panel of microsomes prepared from a series of human livers was significantly correlated with the immunochemically determined levels of CYP2D6 protein (r = 0.925, p < 0.001), and was inhibited (> 89%) by quinidine and lobeline.	Lobeline	268-276	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	180-186
2864237-5	1985	Concomitant treatment of testicular cells with nicotinic cholinergic agonists (lobeline, nicotine, and dimethylphenylpiperazinium iodide) inhibited hCG-stimulated androgen biosynthesis in a dose-dependent fashion, with IC50 values of 3 X 10(-5), 1.7 X 10(-4), and greater than 10(-3) M, respectively.	Lobeline	79-87	hypertrichosis 2 (generalised, congenital)	Homo sapiens	148-151
2864237-7	1985	Lobeline (10-4) M) decreased hCG-stimulated testosterone production (50-75%) throughout the 2-day culture period; however, this inhibition was reversible upon removal of the drug.	Lobeline	0-8	hypertrichosis 2 (generalised, congenital)	Homo sapiens	29-32
2864237-8	1985	Lobeline also inhibited hCG-stimulated cAMP accumulation as well as testosterone production induced by cholera toxin (65% inhibition), forskolin (50% inhibition), or (Bu)2cAMP (70% inhibition).	Lobeline	0-8	hypertrichosis 2 (generalised, congenital)	Homo sapiens	24-27
6254051-3	1980	The half-time of decay (t((1/2))) of endplate currents (e.p.c.s) recorded at a holding potential (V(m)) of -90 mV was significantly shorter in endplates treated with lobeline (50 muM; mean t((1/2)) +/- SEM = 0.41 +/- 0.02 ms) or tubocurarine (11.4 muM; t((1/2)) = 0.64 +/- 0.04 ms) than in those treated with Mg(2+) (13 mM; t((1/2)) = 1.39 +/- 0.11 ms) or a low concentration of tubocurarine (3 muM; t((1/2)) = 0.87 +/- 0.05 ms).	Lobeline	166-174	latexin	Homo sapiens	179-182
6254051-3	1980	The half-time of decay (t((1/2))) of endplate currents (e.p.c.s) recorded at a holding potential (V(m)) of -90 mV was significantly shorter in endplates treated with lobeline (50 muM; mean t((1/2)) +/- SEM = 0.41 +/- 0.02 ms) or tubocurarine (11.4 muM; t((1/2)) = 0.64 +/- 0.04 ms) than in those treated with Mg(2+) (13 mM; t((1/2)) = 1.39 +/- 0.11 ms) or a low concentration of tubocurarine (3 muM; t((1/2)) = 0.87 +/- 0.05 ms).	Lobeline	166-174	latexin	Homo sapiens	248-251
6254051-3	1980	The half-time of decay (t((1/2))) of endplate currents (e.p.c.s) recorded at a holding potential (V(m)) of -90 mV was significantly shorter in endplates treated with lobeline (50 muM; mean t((1/2)) +/- SEM = 0.41 +/- 0.02 ms) or tubocurarine (11.4 muM; t((1/2)) = 0.64 +/- 0.04 ms) than in those treated with Mg(2+) (13 mM; t((1/2)) = 1.39 +/- 0.11 ms) or a low concentration of tubocurarine (3 muM; t((1/2)) = 0.87 +/- 0.05 ms).	Lobeline	166-174	latexin	Homo sapiens	248-251
6254051-4	1980	Similarly, lobeline (10 muM) shortened the t((1/2)) of untreated miniature e.p.c.s by 35%; tubocurarine, however, abolished miniature e.p.c.s at the concentration required to observe its actions on e.p.c.	Lobeline	11-19	latexin	Homo sapiens	24-27
6254051-7	1980	By contrast, the t((1/2))s of e.p.c.s recorded in either lobeline (50 muM) or tubocurarine (11.4 muM) were independent of voltage in the range -150 to -80 mV.	Lobeline	57-65	latexin	Homo sapiens	70-73
6254051-7	1980	By contrast, the t((1/2))s of e.p.c.s recorded in either lobeline (50 muM) or tubocurarine (11.4 muM) were independent of voltage in the range -150 to -80 mV.	Lobeline	57-65	latexin	Homo sapiens	97-100
29427069-3	2018	VMAT2 inhibition by the natural product, lobeline, reduced methamphetamine-evoked dopamine release, methamphetamine-induced hyperlocomotion, and methamphetamine self-administration in rats.	Lobeline	41-49	solute carrier family 18 member A2	Rattus norvegicus	0-5
29133786-5	2017	While either GR32a/GR59c/GR66a or GR22e/GR32a/GR66a heteromultimers are sufficient for lobeline, berberine, and denatonium detection, only GR22e/GR32a/GR66a responds to strychnine.	Lobeline	87-95	Gustatory receptor 32a	Drosophila melanogaster	13-18
29133786-5	2017	While either GR32a/GR59c/GR66a or GR22e/GR32a/GR66a heteromultimers are sufficient for lobeline, berberine, and denatonium detection, only GR22e/GR32a/GR66a responds to strychnine.	Lobeline	87-95	Gustatory receptor 22e	Drosophila melanogaster	34-39
29133786-5	2017	While either GR32a/GR59c/GR66a or GR22e/GR32a/GR66a heteromultimers are sufficient for lobeline, berberine, and denatonium detection, only GR22e/GR32a/GR66a responds to strychnine.	Lobeline	87-95	Gustatory receptor 32a	Drosophila melanogaster	40-45
29133786-5	2017	While either GR32a/GR59c/GR66a or GR22e/GR32a/GR66a heteromultimers are sufficient for lobeline, berberine, and denatonium detection, only GR22e/GR32a/GR66a responds to strychnine.	Lobeline	87-95	Gustatory receptor 66a	Drosophila melanogaster	46-51
29133786-5	2017	While either GR32a/GR59c/GR66a or GR22e/GR32a/GR66a heteromultimers are sufficient for lobeline, berberine, and denatonium detection, only GR22e/GR32a/GR66a responds to strychnine.	Lobeline	87-95	Gustatory receptor 32a	Drosophila melanogaster	40-45
29133786-5	2017	While either GR32a/GR59c/GR66a or GR22e/GR32a/GR66a heteromultimers are sufficient for lobeline, berberine, and denatonium detection, only GR22e/GR32a/GR66a responds to strychnine.	Lobeline	87-95	Gustatory receptor 66a	Drosophila melanogaster	46-51
25921743-5	2015	In this review, the pharmacological efficacy of nAChR ligands, such as mecamylamine, lobeline, cytisine, sazetidine-A, and others will be discussed.	Lobeline	85-93	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	48-53
25636069-9	2015	Using alpha-bungarotoxin, lobeline, and dihydro-beta-erythroidine, we also could show that these effects to various degrees involve alpha7, alpha3/beta2, and alpha4/beta2 n-ChRs.	Lobeline	26-34	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	132-152
25636069-9	2015	Using alpha-bungarotoxin, lobeline, and dihydro-beta-erythroidine, we also could show that these effects to various degrees involve alpha7, alpha3/beta2, and alpha4/beta2 n-ChRs.	Lobeline	26-34	immunoglobulin binding protein 1	Homo sapiens	158-170
26702732-4	2016	Lobeline was tested by inhibiting phosphorylation of mitogen-activated protein kinases (MAPKs), NF-kappaB and IkappaBalpha in LPS-stimulated RAW 264.7 cells.	Lobeline	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	110-122
25451721-1	2015	We have reported that brain nicotinic acetylcholine receptor (nAChR) ligand lobeline has antidepressant-like effects in mice.	Lobeline	76-84	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	28-60
25451721-1	2015	We have reported that brain nicotinic acetylcholine receptor (nAChR) ligand lobeline has antidepressant-like effects in mice.	Lobeline	76-84	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	62-67
24682499-1	2014	RATIONALE: Evidence suggests that neuronal nicotinic acetylcholine receptor (nAChR) ligand lobeline has antidepressant-like properties.	Lobeline	91-99	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	43-75
25451721-8	2015	Lobeline (1 mg/kg) treatment prevented CUS-induced reduction in BDNF expression and cell proliferation in the hippocampus.	Lobeline	0-8	brain derived neurotrophic factor	Mus musculus	64-68
24682499-10	2014	Further, repeated treatment with lobeline or 3-(pyridine-3-yl)-cytisine decreased immobility time in the FST and reduced withdrawal-induced increased BDNF and p-CREB expression in the hippocampus.	Lobeline	33-41	brain derived neurotrophic factor	Mus musculus	150-154
24682499-1	2014	RATIONALE: Evidence suggests that neuronal nicotinic acetylcholine receptor (nAChR) ligand lobeline has antidepressant-like properties.	Lobeline	91-99	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	77-82
24682499-6	2014	Furthermore, we determined the effects of repeated treatment with lobeline or a selective alpha4beta2 nAChR ligand 3-(pyridine-3-yl)-cytisine on brain-derived neurotrophic factor (BDNF) and phosphorylated cAMP-responsive element binding (p-CREB) protein expression in the hippocampus.	Lobeline	66-74	brain derived neurotrophic factor	Mus musculus	145-178
24682499-10	2014	Further, repeated treatment with lobeline or 3-(pyridine-3-yl)-cytisine decreased immobility time in the FST and reduced withdrawal-induced increased BDNF and p-CREB expression in the hippocampus.	Lobeline	33-41	cAMP responsive element binding protein 1	Mus musculus	161-165
24682499-11	2014	CONCLUSIONS: Taken together, our results indicate that lobeline attenuated nicotine withdrawal-induced depression-like behavior likely by targeting brain nAChRs, noradrenergic neurotransmission, and/or hippocampal BDNF.	Lobeline	55-63	brain derived neurotrophic factor	Mus musculus	214-218
23875705-0	2013	Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo.	Lobeline	28-36	solute carrier family 18 member A2	Rattus norvegicus	11-16
24396408-1	2014	We previously demonstrated that lobeline effectively inhibited dopamine transporter (DAT)-mediated dopamine (DA) transportation.	Lobeline	32-40	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	63-83
24396408-1	2014	We previously demonstrated that lobeline effectively inhibited dopamine transporter (DAT)-mediated dopamine (DA) transportation.	Lobeline	32-40	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	85-88
24396408-7	2014	In addition, TH immunostaining showed that lobeline (3 mg/kg) markedly decreased the neurotoxin-induced immunoreactivity loss in the substantia nigra and striatum.	Lobeline	43-51	tyrosine hydroxylase	Mus musculus	13-15
24484975-4	2014	Lobeline, the major alkaloid in Lobelia inflata, potently inhibited VMAT2, methamphetamine-evoked striatal dopamine release, and methamphetamine self-administration in rats but exhibited high affinity for nicotinic acetylcholine receptors (nAChRs).	Lobeline	0-8	solute carrier family 18 member A2	Rattus norvegicus	68-73
24484975-5	2014	Defunctionalized, unsaturated lobeline analog, meso-transdiene (MTD), exhibited lobeline-like in vitro pharmacology, lacked nAChR affinity, but exhibited high affinity for DAT, suggesting potential abuse liability.	Lobeline	30-38	solute carrier family 6 member 3	Rattus norvegicus	172-175
23370310-1	2013	UNLABELLED: Lobeline is a potential smoking cessation drug with affinity for the alpha4beta2 nicotinic acetylcholine receptor and may inhibit the blood-brain barrier (BBB) amine transporter.	Lobeline	12-20	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	93-125
22349182-7	2012	The nicotine-induced Cx43 downregulation functionally impaired intercellular dye transfer, which could be prevented by mecamylamine, kappa-bungarotoxin, lobeline, and dihydro-beta-erythroidine but not alpha-bungarotoxin, indicating that the nAChR subtypes alpha4beta2 and alpha3beta2 but not alpha7 are involved in signal cascade.	Lobeline	153-161	gap junction protein alpha 1	Homo sapiens	21-25
22119644-3	2012	In the current study, lobeline, which interacts with proteins in dopaminergic presynaptic terminals, was evaluated for its ability to attenuate neonatal ethanol-induced locomotor hyperactivity and alterations in dopamine transporter (DAT) function in striatum and prefrontal cortex (PFC).	Lobeline	22-30	solute carrier family 6 member 3	Rattus norvegicus	212-232
22119644-3	2012	In the current study, lobeline, which interacts with proteins in dopaminergic presynaptic terminals, was evaluated for its ability to attenuate neonatal ethanol-induced locomotor hyperactivity and alterations in dopamine transporter (DAT) function in striatum and prefrontal cortex (PFC).	Lobeline	22-30	solute carrier family 6 member 3	Rattus norvegicus	234-237
22119644-12	2012	Thus, lobeline and methylphenidate differentially altered DAT function following neonatal ethanol exposure.	Lobeline	6-14	solute carrier family 6 member 3	Rattus norvegicus	58-61
21964392-2	2011	The objective of present study was to examine anxiolytic effects of lobeline (0.04 or 0.1 mg/kg), a nAChR antagonist, in C57BL/6J mice using elevated plus-maze (EPM) and marble-burying test.	Lobeline	68-76	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	100-105
20876747-1	2011	Lobeline attenuates the behavioral effects of methamphetamine via inhibition of the vesicular monoamine transporter (VMAT2).	Lobeline	0-8	solute carrier family 18 member A2	Homo sapiens	117-122
20734202-0	2010	Effects of lobeline, a nicotinic receptor ligand, on the cloned Kv1.5.	Lobeline	11-19	potassium voltage-gated channel subfamily A member 5	Homo sapiens	64-69
20734202-1	2010	The goal of the present study was to examine the effects of lobeline, an agonist at nicotinic receptors, on cloned Kv channels, Kv1.5, Kv3.1, Kv4.3, and human ether-a-gogo-related gene (HERG), which are stably expressed in Chinese hamster ovary (CHO) or human embryonic kidney 293 (HEK293) cells.	Lobeline	60-68	potassium voltage-gated channel subfamily H member 2	Homo sapiens	186-190
20734202-9	2010	Lobeline produced use-dependent inhibition of Kv1.5 at frequencies of 1 and 2 Hz, and slowed the recovery from inactivation.	Lobeline	0-8	potassium voltage-gated channel subfamily A member 5	Homo sapiens	46-51
20734202-10	2010	Lobeline also inhibited Kv3.1, Kv4.3, and HERG in a concentration-dependent manner, with IC(50) values of 21.7, 28.2, and 0.34 muM, respectively.	Lobeline	0-8	potassium voltage-gated channel subfamily C member 1	Homo sapiens	24-29
20734202-10	2010	Lobeline also inhibited Kv3.1, Kv4.3, and HERG in a concentration-dependent manner, with IC(50) values of 21.7, 28.2, and 0.34 muM, respectively.	Lobeline	0-8	potassium voltage-gated channel subfamily D member 3	Homo sapiens	31-36
20734202-10	2010	Lobeline also inhibited Kv3.1, Kv4.3, and HERG in a concentration-dependent manner, with IC(50) values of 21.7, 28.2, and 0.34 muM, respectively.	Lobeline	0-8	potassium voltage-gated channel subfamily H member 2	Homo sapiens	42-46
20734202-10	2010	Lobeline also inhibited Kv3.1, Kv4.3, and HERG in a concentration-dependent manner, with IC(50) values of 21.7, 28.2, and 0.34 muM, respectively.	Lobeline	0-8	latexin	Homo sapiens	127-130
20734202-11	2010	These results indicate that lobeline produces a concentration-, time-, voltage-, and use-dependent inhibition of Kv1.5, which can be interpreted as an open-channel block mechanism.	Lobeline	28-36	potassium voltage-gated channel subfamily A member 5	Homo sapiens	113-118
19855096-2	2010	Lobeline interacts with nicotinic receptor subtypes, dopamine transporters (DATs), and vesicular monoamine transporters (VMAT2s).	Lobeline	0-8	solute carrier family 18 member A2	Homo sapiens	121-126
19855096-5	2010	Compared with lobeline, the analogs exhibited greater potency inhibiting DA transporter (DAT) function.	Lobeline	14-22	solute carrier family 6 member 3	Homo sapiens	73-87
19855096-5	2010	Compared with lobeline, the analogs exhibited greater potency inhibiting DA transporter (DAT) function.	Lobeline	14-22	solute carrier family 6 member 3	Homo sapiens	89-92
20036131-2	2010	Lobeline (1) is a potent antagonist at alpha4beta2 * nicotinic acetylcholine receptors, has moderate affinity (K(i)=5.46microM) for VMAT2, and is being investigated currently as a clinical candidate for treatment of psychostimulant abuse.	Lobeline	0-8	solute carrier family 18 member A2	Rattus norvegicus	132-137
20036131-10	2010	Thus, esterification of the lobeline molecule may be a useful structural modification for the development of lobeline analogs with improved selectivity at VMAT2.	Lobeline	28-36	solute carrier family 18 member A2	Rattus norvegicus	155-160
20036131-10	2010	Thus, esterification of the lobeline molecule may be a useful structural modification for the development of lobeline analogs with improved selectivity at VMAT2.	Lobeline	109-117	solute carrier family 18 member A2	Rattus norvegicus	155-160
19765987-8	2009	Gr33a mutant flies were impaired in avoiding all nonvolatile repellents tested, ranging from quinine to denatonium, lobeline, and caffeine.	Lobeline	116-124	Gustatory receptor 33a	Drosophila melanogaster	0-5
18191815-1	2008	The mechanisms of interaction between lobeline and the dopamine transporter (DAT) or the vesicular monoamine transporter (VMAT-2) are not clear.	Lobeline	38-46	solute carrier family 6 member 3	Homo sapiens	55-75
18191815-1	2008	The mechanisms of interaction between lobeline and the dopamine transporter (DAT) or the vesicular monoamine transporter (VMAT-2) are not clear.	Lobeline	38-46	solute carrier family 6 member 3	Homo sapiens	77-80
18191815-3	2008	Lobeline caused release of [(3)H]dopamine to a similar extent as reserpine (VMAT-2 inhibitor), but was less efficacious than methamphetamine or dopamine.	Lobeline	0-8	solute carrier family 18 member A2	Homo sapiens	76-82
18191815-5	2008	These results suggest that lobeline has unique properties at the DAT and VMAT-2 which may make it useful as a pharmacotherapeutic to treat methamphetamine abuse.	Lobeline	27-35	solute carrier family 6 member 3	Homo sapiens	65-68
18191815-5	2008	These results suggest that lobeline has unique properties at the DAT and VMAT-2 which may make it useful as a pharmacotherapeutic to treat methamphetamine abuse.	Lobeline	27-35	solute carrier family 18 member A2	Homo sapiens	73-79
19734580-3	2009	Fluorospectorphotometer was employed to investigate the intracellular concentration of rhodamine123 to reflect the effect of lobeline on the activity of MDR-related protein P-glycoprotein (P-gp).	Lobeline	125-133	ATP binding cassette subfamily B member 1	Homo sapiens	173-187
19734580-3	2009	Fluorospectorphotometer was employed to investigate the intracellular concentration of rhodamine123 to reflect the effect of lobeline on the activity of MDR-related protein P-glycoprotein (P-gp).	Lobeline	125-133	ATP binding cassette subfamily B member 1	Homo sapiens	189-193
19734580-10	2009	CONCLUSION: Lobeline can reverse the MDR of MCF-7/ADM cells by inhibiting the activity of P-glycoprotein.	Lobeline	12-20	ATP binding cassette subfamily B member 1	Homo sapiens	90-104